Association Between Macular Amyloidosis and Autoimmune Hepatitis
Yes, there is a documented association between macular amyloidosis and autoimmune hepatitis, though it is rare and likely represents a shared autoimmune pathogenic mechanism rather than a direct causal relationship.
Evidence for the Association
The connection between these two conditions has been documented in case reports and small case series, particularly in the context of autoimmune liver diseases:
Direct case documentation exists: A case report specifically describes cutaneous amyloidosis occurring with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome 1. Another case report from 2018 documented primary cutaneous amyloidosis associated with AIH-PBC overlap syndrome and Sjögren syndrome, suggesting a common immune-mediated pathogenic pathway 2.
The association appears strongest with overlap syndromes: Both documented cases involved AIH-PBC overlap rather than isolated AIH, which may indicate that patients with multiple autoimmune features are at higher risk for developing cutaneous manifestations 1, 2.
Proposed Pathophysiological Mechanism
The relationship likely reflects:
Shared autoimmune dysregulation: The co-occurrence suggests a common immune-mediated pathogenic pathway rather than one condition causing the other 2. Patients with autoimmune hepatitis have underlying immune dysregulation that may predispose them to other autoimmune manifestations.
Chronic liver disease as a contributing factor: One case series noted that patients with chronic liver disease and pruritus developed both macular amyloidosis and prurigo nodularis in scratched areas, suggesting that liver disease-associated pruritus and subsequent friction may contribute to amyloid deposition 3.
Clinical Implications for Your Patient
Your patient's concurrent conditions should be managed independently, as there is no evidence that treating one will improve the other:
Manage AIH according to standard guidelines: Follow the 2025 EASL and BSG guidelines for AIH management with standard immunosuppression (corticosteroids ± azathioprine) 4, 5. The presence of macular amyloidosis does not alter AIH treatment strategy.
Treat macular amyloidosis symptomatically: High-potency topical corticosteroids for symptomatic relief of pruritus remain the standard approach 6. The 12-year follow-up case showed that immunosuppression for AIH (UDCA, prednisone, azathioprine) did not prevent progression of cutaneous amyloidosis 2.
Monitor for additional autoimmune conditions: Given the documented association with multiple autoimmune diseases (Sjögren syndrome, PBC overlap), consider screening for other autoimmune conditions if clinically indicated 2.
Important Caveats
This is an extremely rare association: Only isolated case reports exist in the literature, so the true prevalence and strength of association remain unclear.
Causality is not established: The temporal relationship and whether one condition predisposes to the other has not been determined.
Document the association: Consider reporting this case to contribute to the limited literature on this rare co-occurrence.